Korea FDA To Approve First Stem Cell Therapy For Myocardial Infarction
This article was originally published in PharmAsia News
Executive Summary
SEOUL - In what might be marked as the world's first approved stem-cell medication, Korea FDA plans to approve in early July Hearticellgram-AMI, a stem cell therapy for acute myocardial infarction, developed by Korean bioventure FCB-Pharmicell